Collapse to view only § 1604. Liability of biomaterials suppliers

§ 1601. FindingsThe Congress finds that—
(1) each year millions of citizens of the United States depend on the availability of lifesaving or life-enhancing medical devices, many of which are permanently implantable within the human body;
(2) a continued supply of raw materials and component parts is necessary for the invention, development, improvement, and maintenance of the supply of the devices;
(3) most of the medical devices are made with raw materials and component parts that—
(A) move in interstate commerce;
(B) are not designed or manufactured specifically for use in medical devices; and
(C) come in contact with internal human tissue;
(4) the raw materials and component parts also are used in a variety of nonmedical products;
(5) because small quantities of the raw materials and component parts are used for medical devices, sales of raw materials and component parts for medical devices constitute an extremely small portion of the overall market for the raw materials and component parts;
(6) under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) manufacturers of medical devices are required to demonstrate that the medical devices are safe and effective, including demonstrating that the products are properly designed and have adequate warnings or instructions;
(7) notwithstanding the fact that raw materials and component parts suppliers do not design, produce, or test a final medical device, the suppliers have been the subject of actions alleging inadequate—
(A) design and testing of medical devices manufactured with materials or parts supplied by the suppliers; or
(B) warnings related to the use of such medical devices;
(8) even though suppliers of raw materials and component parts have very rarely been held liable in such actions, such suppliers have ceased supplying certain raw materials and component parts for use in medical devices for a number of reasons, including concerns about the costs of such litigation;
(9) unless alternate sources of supply can be found, the unavailability of raw materials and component parts for medical devices will lead to unavailability of lifesaving and life-enhancing medical devices;
(10) because other suppliers of the raw materials and component parts in foreign nations are refusing to sell raw materials or component parts for use in manufacturing certain medical devices in the United States, the prospects for development of new sources of supply for the full range of threatened raw materials and component parts for medical devices are remote;
(11) it is unlikely that the small market for such raw materials and component parts in the United States could support the large investment needed to develop new suppliers of such raw materials and component parts;
(12) attempts to develop such new suppliers would raise the cost of medical devices;
(13) courts that have considered the duties of the suppliers of the raw materials and component parts have generally found that the suppliers do not have a duty—
(A) to evaluate the safety and efficacy of the use of a raw material or component part in a medical device; or
(B) to warn consumers concerning the safety and effectiveness of a medical device;
(14) because medical devices and the raw materials and component parts used in their manufacture move in interstate commerce, a shortage of such raw materials and component parts affects interstate commerce;
(15) in order to safeguard the availability of a wide variety of lifesaving and life-enhancing medical devices, immediate action is needed—
(A) to clarify the permissible bases of liability for suppliers of raw materials and component parts for medical devices; and
(B) to provide expeditious procedures to dispose of unwarranted suits against the suppliers in such manner as to minimize litigation costs;
(16) the several States and their courts are the primary architects and regulators of our tort system; Congress, however, must, in certain circumstances involving the national interest, address tort issues, and a threatened shortage of raw materials and component parts for lifesaving medical devices is one such circumstance; and
(17) the protections set forth in this chapter are needed to assure the continued supply of materials for lifesaving medical devices, although such protections do not protect negligent suppliers.
(Pub. L. 105–230, § 2, Aug. 13, 1998, 112 Stat. 1519.)
§ 1602. Definitions As used in this chapter:
(1) Biomaterials supplier
(A) In general
(B) Persons includedSuch term includes any person who—
(i) has submitted master files to the Secretary for purposes of premarket approval of a medical device; or
(ii) licenses a biomaterials supplier to produce component parts or raw materials.
(2) Claimant
(A) In general
(B) Action brought on behalf of an estate
(C) Action brought on behalf of a minor or incompetent
(D) ExclusionsSuch term does not include—
(i) a provider of professional health care services in any case in which—(I) the sale or use of an implant is incidental to such services; and(II) the essence of the professional health care services provided is the furnishing of judgment, skill, or services;
(ii) a person acting in the capacity of a manufacturer, seller, or biomaterials supplier; or
(iii) a person alleging harm caused by either the silicone gel or the silicone envelope utilized in a breast implant containing silicone gel, except that—(I) neither the exclusion provided by this clause nor any other provision of this chapter may be construed as a finding that silicone gel (or any other form of silicone) may or may not cause harm; and(II) the existence of the exclusion under this clause may not—(aa) be disclosed to a jury in any civil action or other proceeding; and(bb) except as necessary to establish the applicability of this chapter, otherwise be presented in any civil action or other proceeding.
(3) Component part
(A) In general
(B) Certain componentsSuch term includes a manufactured piece of an implant that—
(i) has significant non-implant applications; and
(ii) alone, has no implant value or purpose, but when combined with other component parts and materials, constitutes an implant.
(4) Harm
(A) In generalThe term “harm” means—
(i) any injury to or damage suffered by an individual;
(ii) any illness, disease, or death of that individual resulting from that injury or damage; and
(iii) any loss to that individual or any other individual resulting from that injury or damage.
(B) Exclusion
(5) ImplantThe term “implant” means—
(A) a medical device that is intended by the manufacturer of the device—
(i) to be placed into a surgically or naturally formed or existing cavity of the body for a period of at least 30 days; or
(ii) to remain in contact with bodily fluids or internal human tissue through a surgically produced opening for a period of less than 30 days; and
(B) suture materials used in implant procedures.
(6) ManufacturerThe term “manufacturer” means any person who, with respect to an implant—
(A) is engaged in the manufacture, preparation, propagation, compounding, or processing (as defined in section 360(a)(1) of this title) of the implant; and
(B) is required—
(i) to register with the Secretary pursuant to section 360 of this title and the regulations issued under such section; and
(ii) to include the implant on a list of devices filed with the Secretary pursuant to section 360(j) of this title and the regulations issued under such section.
(7) Medical device
(8) Raw materialThe term “raw material” means a substance or product that—
(A) has a generic use; and
(B) may be used in an application other than an implant.
(9) Secretary
(10) Seller
(A) In general
(B) ExclusionsThe term does not include—
(i) a seller or lessor of real property;
(ii) a provider of professional health care services in any case in which—(I) the sale or use of the implant is incidental to such services; and(II) the essence of the professional health care services provided is the furnishing of judgment, skill, or services; or
(iii) any person who acts in only a financial capacity with respect to the sale of an implant.
(Pub. L. 105–230, § 3, Aug. 13, 1998, 112 Stat. 1520.)
§ 1603. General requirements; applicability; preemption
(a) General requirements
(1) In general
In any civil action covered by this chapter, a biomaterials supplier may—
(A) raise any exclusion from liability set forth in section 1604 of this title; and
(B) make a motion for dismissal or for summary judgment as set forth in section 1605 of this title.
(2) Procedures
(b) Applicability
(1) In general
(2) Exclusion
A civil action brought by a purchaser of a medical device, purchased for use in providing professional health care services, for loss or damage to an implant or for commercial loss to the purchaser—
(A) shall not be considered an action that is subject to this chapter; and
(B) shall be governed by applicable commercial or contract law.
(c) Scope of preemption
(1) In general
(2) Applicability of other laws
(d) Statutory construction
Nothing in this chapter may be construed—
(1) to affect any defense available to a defendant under any other provisions of Federal or State law in an action alleging harm caused by an implant; or
(2) to create a cause of action or Federal court jurisdiction pursuant to section 1331 or 1337 of title 28 that otherwise would not exist under applicable Federal or State law.
(Pub. L. 105–230, § 4, Aug. 13, 1998, 112 Stat. 1523.)
§ 1604. Liability of biomaterials suppliers
(a) In generalExcept as provided in section 1606 of this title, a biomaterials supplier shall not be liable for harm to a claimant caused by an implant unless such supplier is liable—
(1) as a manufacturer of the implant, as provided in subsection (b);
(2) as a seller of the implant, as provided in subsection (c); or
(3) for furnishing raw materials or component parts for the implant that failed to meet applicable contractual requirements or specifications, as provided in subsection (d).
(b) Liability as manufacturer
(1) In general
(2) Grounds for liabilityThe biomaterials supplier may be considered the manufacturer of the implant that allegedly caused harm to a claimant only if the biomaterials supplier—
(A)
(i) registered or was required to register with the Secretary pursuant to section 360 of this title and the regulations issued under such section; and
(ii) included or was required to include the implant on a list of devices filed with the Secretary pursuant to section 360(j) of this title and the regulations issued under such section;
(B) is the subject of a declaration issued by the Secretary pursuant to paragraph (3) that states that the supplier, with respect to the implant that allegedly caused harm to the claimant, was required to—
(i) register with the Secretary under section 360 of this title, and the regulations issued under such section, but failed to do so; or
(ii) include the implant on a list of devices filed with the Secretary pursuant to section 360(j) of this title and the regulations issued under such section, but failed to do so; or
(C) is related by common ownership or control to a person meeting all the requirements described in subparagraph (A) or (B), if the court deciding a motion to dismiss in accordance with section 1605(c)(3)(B)(i) of this title finds, on the basis of affidavits submitted in accordance with section 1605 of this title, that it is necessary to impose liability on the biomaterials supplier as a manufacturer because the related manufacturer meeting the requirements of subparagraph (A) or (B) lacks sufficient financial resources to satisfy any judgment that the court feels it is likely to enter should the claimant prevail.
(3) Administrative procedures
(A) In generalThe Secretary may issue a declaration described in paragraph (2)(B) on the motion of the Secretary or on petition by any person, after providing—
(i) notice to the affected persons; and
(ii) an opportunity for an informal hearing.
(B) Docketing and final decision
(C) Applicability of statute of limitations
(D) Stay pending petition for declaration
(c) Liability as sellerA biomaterials supplier may, to the extent required and permitted by any other applicable law, be liable as a seller for harm to a claimant caused by an implant only if—
(1) the biomaterials supplier—
(A) held title to the implant and then acted as a seller of the implant after its initial sale by the manufacturer; or
(B) acted under contract as a seller to arrange for the transfer of the implant directly to the claimant after the initial sale by the manufacturer of the implant; or
(2) the biomaterials supplier is related by common ownership or control to a person meeting all the requirements described in paragraph (1), if a court deciding a motion to dismiss in accordance with section 1605(c)(3)(B)(ii) of this title finds, on the basis of affidavits submitted in accordance with section 1605 of this title, that it is necessary to impose liability on the biomaterials supplier as a seller because the related seller meeting the requirements of paragraph (1) lacks sufficient financial resources to satisfy any judgment that the court feels it is likely to enter should the claimant prevail.
(d) Liability for failure to meet applicable contractual requirements or specifications
(1) the biomaterials supplier supplied raw materials or component parts for use in the implant that either—
(A) did not constitute the product described in the contract between the biomaterials supplier and the person who contracted for the supplying of the product; or
(B) failed to meet any specifications that were—
(i) accepted, pursuant to applicable law, by the biomaterials supplier;
(ii) published by the biomaterials supplier;
(iii) provided by the biomaterials supplier to the person who contracted for such product;
(iv) contained in a master file that was submitted by the biomaterials supplier to the Secretary and that is currently maintained by the biomaterials supplier for purposes of premarket approval of medical devices; or
(v) included in the submissions for purposes of premarket approval or review by the Secretary under section 360, 360c, 360e, or 360j of this title, and received clearance from the Secretary if such specifications were accepted, pursuant to applicable law, by the biomaterials supplier; and
(2) such failure to meet applicable contractual requirements or specifications was an actual and proximate cause of the harm to the claimant.
(Pub. L. 105–230, § 5, Aug. 13, 1998, 112 Stat. 1524.)
§ 1605. Procedures for dismissal of civil actions against biomaterials suppliers
(a) Motion to dismissA defendant may, at any time during which a motion to dismiss may be filed under applicable law, move to dismiss an action against it on the grounds that the defendant is a biomaterials supplier and one or more of the following:
(1) The defendant is not liable as a manufacturer, as provided in section 1604(b) of this title.
(2) The defendant is not liable as a seller, as provided in section 1604(c) of this title.
(3) The defendant is not liable for furnishing raw materials or component parts for the implant that failed to meet applicable contractual requirements or specifications, as provided in section 1604(d) of this title.
(4) The claimant did not name the manufacturer as a party to the action, as provided in subsection (b).
(b) Manufacturer of implant shall be named a partyIn any civil action covered by this chapter, the claimant shall be required to name the manufacturer of the implant as a party to the action, unless—
(1) the manufacturer is subject to service of process solely in a jurisdiction in which the biomaterials supplier is not domiciled or subject to a service of process; or
(2) a claim against the manufacturer is barred by applicable law or rule of practice.
(c) Proceeding on motion to dismissThe following rules shall apply to any proceeding on a motion to dismiss filed by a defendant under this section:
(1) Effect of motion to dismiss on discovery
(A) In general
(B) DiscoveryIf a defendant files a motion to dismiss under subsection (a)(3) on the grounds that it did not furnish raw materials or component parts for the implant that failed to meet applicable contractual requirements or specifications, the court may permit discovery limited to issues that are directly relevant to—
(i) the pending motion to dismiss; or
(ii) the jurisdiction of the court.
(2) Affidavits
(A) Defendant
(B) ClaimantIn response to a motion to dismiss, the claimant may submit affidavits demonstrating that—
(i) the Secretary has, with respect to the defendant and the implant that allegedly caused harm to the claimant, issued a declaration pursuant to section 1604(b)(2)(B) of this title; or
(ii) the defendant is a seller of the implant who is liable under section 1604(c) of this title.
(3) Basis of ruling on motion to dismissThe court shall rule on a motion to dismiss filed under subsection (a) solely on the basis of the pleadings and affidavits of the parties made pursuant to this subsection. The court shall grant a motion to dismiss filed under subsection (a)—
(A) unless the claimant submits a valid affidavit that demonstrates that the defendant is not a biomaterials supplier;
(B) unless the court determines, to the extent raised in the pleadings and affidavits, that one or more of the following apply:
(i) the defendant may be liable as a manufacturer, as provided in section 1604(b) of this title;
(ii) the defendant may be liable as a seller, as provided in section 1604(c) of this title; or
(iii) the defendant may be liable for furnishing raw materials or component parts for the implant that failed to meet applicable contractual requirements or specifications, as provided in section 1604(d) of this title; or
(C) if the claimant did not name the manufacturer as a party to the action, as provided in subsection (b).
(4) Treatment of motion as motion for summary judgment
(d) Summary judgment
(1) In general
(A) Basis for entry of judgment
(B) Issues of material fact
(2) Discovery made prior to a ruling on a motion for summary judgment
(3) Discovery with respect to a biomaterials supplier
(e) Dismissal with prejudice
(f) Manufacturer conduct of litigation
(Pub. L. 105–230, § 6, Aug. 13, 1998, 112 Stat. 1526.)
§ 1606. Subsequent impleader of dismissed biomaterials supplier
(a) Impleading of dismissed defendantA court, upon motion by a manufacturer or a claimant within 90 days after entry of a final judgment in an action by the claimant against a manufacturer, and notwithstanding any otherwise applicable statute of limitations, may implead a biomaterials supplier who has been dismissed from the action pursuant to this chapter if—
(1) the manufacturer has made an assertion, either in a motion or other pleading filed with the court or in an opening or closing statement at trial, or as part of a claim for contribution or indemnification, and the court finds based on the court’s independent review of the evidence contained in the record of the action, that under applicable law—
(A) the negligence or intentionally tortious conduct of the dismissed supplier was an actual and proximate cause of the harm to the claimant; and
(B) the manufacturer’s liability for damages should be reduced in whole or in part because of such negligence or intentionally tortious conduct; or
(2) the claimant has moved to implead the supplier and the court finds, based on the court’s independent review of the evidence contained in the record of the action, that under applicable law—
(A) the negligence or intentionally tortious conduct of the dismissed supplier was an actual and proximate cause of the harm to the claimant; and
(B) the claimant is unlikely to be able to recover the full amount of its damages from the remaining defendants.
(b) Standard of liabilityNotwithstanding any preliminary finding under subsection (a), a biomaterials supplier who has been impleaded into an action covered by this chapter, as provided for in this section—
(1) may, prior to entry of judgment on the claim against it, supplement the record of the proceeding that was developed prior to the grant of the motion for impleader under subsection (a); and
(2) may be found liable to a manufacturer or a claimant only to the extent required and permitted by any applicable State or Federal law other than this chapter.
(c) Discovery
(Pub. L. 105–230, § 7, Aug. 13, 1998, 112 Stat. 1528.)